TransMedics Group (NASDAQ:TMDX) Shares Up 7.4% – Time to Buy?

TransMedics Group, Inc. (NASDAQ:TMDX) traded up 7.4% on Wednesday . The company traded as high as $73.59 and last traded at $73.30. 870,970 shares changed hands during mid-day trading, a decline of 34% from the average session volume of 1,319,089 shares. The stock had previously closed at $68.27.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on TMDX shares. Robert W. Baird cut their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Canaccord Genuity Group restated a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler dropped their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Down 4.6 %

The firm’s fifty day moving average is $69.93 and its 200-day moving average is $86.32. The company has a market capitalization of $2.28 billion, a P/E ratio of 71.99 and a beta of 2.14. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

Institutional Trading of TransMedics Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. Clear Creek Financial Management LLC acquired a new stake in shares of TransMedics Group during the 4th quarter valued at $352,000. Vaughan Nelson Investment Management L.P. raised its position in TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock valued at $22,547,000 after purchasing an additional 32,605 shares during the last quarter. Baillie Gifford & Co. boosted its stake in shares of TransMedics Group by 14.9% during the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock valued at $16,824,000 after purchasing an additional 34,947 shares in the last quarter. State of Michigan Retirement System bought a new stake in shares of TransMedics Group during the fourth quarter worth about $6,734,000. Finally, Zacks Investment Management acquired a new position in shares of TransMedics Group in the third quarter valued at approximately $1,607,000. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.